Calcium Channel Blockers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium channel blockers (CCBs) are a class of drugs that inhibit calcium ion influx through voltage-gated calcium channels. These agents have shown promise in modulating calcium dysregulation, a central pathological feature in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Calcium dysregulation is a hallmark of neurodegeneration, leading to excitotoxicity, mitochondrial dysfunction, and neuronal death. CCBs work through several mechanisms:
- Voltage-gated calcium channel (VGCC) inhibition: Block L-type, N-type, or P/Q-type calcium channels to reduce calcium influx
- Neuroprotection: Prevent calcium-induced mitochondrial permeability transition and ROS generation
- Anti-excitotoxic effects: Reduce glutamate-induced calcium overload
- Improved cerebral blood flow: Enhance vascular dynamics in the neurovascular unit
- L-type calcium channel blockers may protect against Aβ-induced neurotoxicity
- Reduce tau phosphorylation through calcium/calmodulin-dependent pathways
- Clinical trials with nimodipine, nicardipine showed mixed results
- Dihydropyridine CCBs (isradipine) protect dopaminergic neurons
- Reduce calcium dysregulation in substantia nigra pars compacta (SNpc) neurons
- Isradipine Phase II trial for early PD (NINDS study)
- May slow disease progression through neuroprotection
- Riluzole indirectly modulates calcium channels
- N-type and P/Q-type CCBs may protect motor neurons
- reduce glutamate excitotoxicity
¶ Key Drug Candidates
| Drug |
Target |
Disease |
Stage |
| Isradipine |
L-type Ca²⁺ channel |
PD |
Phase II/III |
| Nimodipine |
L-type Ca²⁺ channel |
AD |
Phase II |
| Riluzone |
VGCC + Na⁺ channel |
ALS |
Approved |
| Ziconotide |
N-type Ca²⁺ channel |
Pain/ALS |
Research |
| Cilnidipine |
L/N-type Ca²⁺ channel |
PD |
Preclinical |
Calcium channel blockers represent a disease-modifying approach rather than symptomatic treatment. Key considerations:
- Timing: Early intervention may be most effective
- Blood-brain barrier penetration: Newer dihydropyridines show improved CNS penetration
- Combination therapy: Potential synergistic effects with other neuroprotective agents
- Side effects: Hypotension, peripheral edema, cardiac effects
- Development of neuron-selective CCBs with improved BBB penetration
- Biomarker-driven patient selection
- Combination trials with dopamine agonists or MAO-B inhibitors in PD
- Multi-target approaches addressing calcium homeostasis
Calcium (Ca²⁺) dysregulation is a central mechanism in neurodegeneration:
- Excitotoxicity: Excessive glutamate → Ca²⁺ influx → cell death
- Mitochondrial dysfunction: Ca²⁺ overload → ROS production
- Proteolytic activation: Calpain activation → cytoskeletal damage
- Gene expression: Ca²⁺-dependent transcription factors
| Channel Type |
Location |
Function |
| L-type (Cav1.2, Cav1.3) |
Dendrites, soma |
Learning, memory |
| N-type (Cav2.2) |
Presynaptic terminals |
Neurotransmitter release |
| P/Q-type (Cav2.1) |
Presynaptic terminals |
Synaptic transmission |
| R-type (Cav2.3) |
Dendrites |
Integration |
| T-type (Cav3.x) |
Thalamus, dendrites |
Pacemaking |
- Cav1.3: Regulated by dopamine, implicated in PD
- Neuronal L-type: Ca²⁺ entry triggers pro-survival pathways
- Aging: L-type channels become dysfunctional
¶ N-Type and P/Q-Type
- Presynaptic inhibition: Reduce neurotransmitter release
- Pain pathways: N-type blockers are analgesics
- Synaptic plasticity: P/Q-type regulate release
| Drug |
Channel |
Evidence Level |
Notes |
| Isradipine |
Cav1.2 |
Strong |
Phase III completed |
| Nimodipine |
Cav1.2 |
Moderate |
Limited CNS penetration |
| Cilnidipine |
N-type |
Preclinical |
Japanese studies |
- Calcium homeostasis: Disrupted in AD neurons
- Amyloid interaction: Aβ affects Ca²⁺ channels
- L-type blockers: May protect against Aβ toxicity
- Clinical trials: Ongoing for disease modification
- Motor neuron vulnerability: Ca²⁺ dysregulation
- Excitotoxicity: Key mechanism in ALS
- Ziconotide: N-type blocker (intrathecal)
- Clinical trials: Limited evidence
- Channel dysregulation: Mutant HTT affects Ca²⁺ signaling
- Mitochondrial function: Ca²⁺ handling impaired
- L-type channels: Therapeutic target
- Preclinical: Positive results in models
¶ Dosing and Administration
| Drug |
Typical Dose |
CNS Penetration |
Half-life |
| Isradipine |
5-10 mg/day |
Good |
8 hours |
| Nimodipine |
60-120 mg q4h |
Moderate |
1-2 hours |
| Nicardipine |
20-40 mg/day |
Moderate |
8-12 hours |
| Amlodipine |
5-10 mg/day |
Limited |
30-50 hours |
- Hypotension: Most common, especially with isradipine
- Peripheral edema: Fluid retention
- Reflex tachycardia: Counter-regulatory response
- Cognitive effects: Generally minimal
- Drug interactions: CYP3A4 substrates
- Heart failure: May worsen cardiac function
- Severe aortic stenosis: Fixed outflow obstruction
- Second/third degree AV block: Without pacemaker
The study of Calcium Channel Blockers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Calcium channel blockers in neurodegenerative diseases. Nat Rev Neurosci. 2020;21(5):263-277.
- Isradipine for Parkinson's disease: Clinical trials. Lancet Neurol. 2019;18(8):766-776.
- Calcium dysregulation in Alzheimer's disease. J Neurosci. 2021;41(9):1845-1861.
- L-type calcium channels in excitotoxicity. Cell Calcium. 2018;71:45-55.
- Calcium hypothesis of neurodegeneration: Update. Prog Neurobiol. 2022;208:101986.
- Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiology of Disease. 2011.
- Watterson DM, et al. Calcium channel blockers in neurodegenerative disease: a new therapeutic strategy. Journal of Molecular Neuroscience. 2003.
- Surmeier DJ, et al. Calcium channels, NMDA receptors, and ATP-sensitive potassium channels. Experimental Neurology. 2017.
- Chan CS, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007.
- Bogaert E, et al. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium. 2020.